Welcome to our dedicated page for Phreesia SEC filings (Ticker: PHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding Phreesia’s patient-volume metrics or HIPAA compliance costs inside a 250-page filing can slow any analyst. Healthcare SaaS companies combine software revenue rules with healthcare regulations, making disclosures tough to parse. That’s why Stock Titan’s AI deciphers Phreesia SEC filings explained simply—turning dense accounting notes and regulatory risk sections into plain-language highlights.
Need to spot how subscription renewals trend across medical groups in the latest Phreesia quarterly earnings report 10-Q filing? Curious whether executives trimmed holdings before a product launch? Our platform links each disclosure to what matters for this business: 10-Ks outline retention rates and payment-processing margins, 8-K material events explained show new EHR partnerships, and every proxy statement executive compensation details incentive plans aligned with patient engagement growth. Meanwhile, real-time alerts surface Phreesia insider trading Form 4 transactions the moment they hit EDGAR, so you can monitor executive stock transactions Form 4 without refreshing the site.
Here’s how professionals use these insights: compare segment revenue across consecutive reports, track Form 4 insider transactions real-time to gauge leadership sentiment, and export AI summaries to brief stakeholders faster than manual review. Whether you’re understanding Phreesia SEC documents with AI for diligence, or need a Phreesia annual report 10-K simplified for board decks, Stock Titan keeps you current—complete coverage, automatic updates, and AI-driven earnings report filing analysis in one place.
Phreesia, Inc. (PHR) has filed a Form 144 indicating that shareholder Yvonne Hui intends to sell 307 common shares, worth about $8,371.83, through Fidelity Brokerage on or about 15 July 2025. With 59,504,269 shares outstanding, the planned sale represents roughly 0.0005% of the company’s float.
The filing also discloses that the same seller disposed of 4,208 shares over the past three months in six separate transactions, generating gross proceeds of approximately $104,610. The 307 shares being registered for sale were acquired on 11 July 2025 via restricted-stock vesting and constitute compensation-related stock.
The notice includes the standard certification that the seller is unaware of any non-public adverse information about Phreesia. Given the very small size relative to total shares outstanding and the routine nature of Rule 144 sales, this event is unlikely to be materially impactful for investors.
On July 2, 2025, Phreesia, Inc. (PHR) director Mark Douglas Smith filed a Form 4 disclosing an option exercise and immediate share sale under a pre-arranged Rule 10b5-1 plan.
- Option exercise (Code M): 7,000 shares converted at an exercise price of $4.71.
- Open-market sale (Code S): the same 7,000 shares sold at $29.00 per share, generating roughly $203k gross proceeds.
- After the transactions, Smith’s direct ownership declined from 44,353 to 37,353 common shares.
- The underlying stock option was fully vested and would have expired on September 4, 2028; no derivative holdings remain related to this grant (51,193 total derivative securities now held).
The activity represents a 15.8 % reduction in Smith’s directly held shares. Because the sale was executed pursuant to a 10b5-1 plan adopted on January 10, 2025, market-timing concerns are mitigated, although investors may still view insider net selling as a modest negative signal.
FAQ
What is the current stock price of Phreesia (PHR)?
What is the market cap of Phreesia (PHR)?
